
    
      Eligible patient population:

        -  Stage 4 breast cancer

        -  Resolution from toxicity of prior therapy to â‰¤ CTC grade 1 ( except alopecia)

        -  No limit on prior number of therapies to treat cancer

        -  Adequate organ function

        -  Life expectancy greater than 3 months

      Treatment: ixabepilone 40 mg/m2 Q3w over 3 hours

      Evaluation on Study:

      I. Efficacy evaluation:

        -  Baseline CT chest, abdomen and pelvis and bone scan within 4 weeks of starting therapy

        -  Evaluation of disease every 2 cycles of chemotherapy

        -  Ongoing toxicity evaluation using NCI CTC 3.

      II. Neurological evaluation:

        -  Detailed neurologic exam using Neuropathy Assessment Instrument (represents a standard
           neurological exam)

        -  Serum NGF, IL 8,10, prior to starting therapy and prior to each cycle of ixabepilone

        -  DNA for assessment of TRK A and MDR1 polymorphisms

        -  Punch biopsy of skin prior to starting therapy and after every 2 cycles. Laboratory
           evaluation of peripheral nerve biopsies will be conducted at Rockefeller University
           under the direction of Dr. Carlson in Dr. Strickland's Lab.
    
  